A Phase 2 interventional study of IFN beta-1a and Dexamethasone in Covid19, sponsored by Faron Pharmaceuticals Ltd. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-21.
Sponsored by Faron Pharmaceuticals Ltd · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing Interferon beta-1a in COVID-19 — 1 open to participants now, 1 under way, 1 of them phase 3. Interferon beta-1a · COVID-19.
Among the 12 studies testing Interferon beta-1a in COVID-19, this one is the 12th largest by enrollment, is one of 3 that started in 2021, is one of 4 in phase 2, and was the 11th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →1 of the 12 studies testing Interferon beta-1a in COVID-19 is open now, in 12 countries. Recruiting first, the newest first:
UMC Utrecht · Sites in United States, Australia, Belgium and 26 more countries
Ages 28 days+
By country, each count listing its studies:
Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 6 · Phase 4 1
First in 2016; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 422 across the 12 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 8 most frequent:
Faron Pharmaceuticals Ltd is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Faron Pharmaceuticals Ltd has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing Interferon beta-1a in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This double-blinded, randomized study is being conducted to see if the investigational new drug called FP-1201-lyo - intravenous Interferon beta-1a, hereafter IV IFN beta-1a, can help patients recover more quickly from COVID-19 and prevent worsening of the condition. To understand if IV IFN beta-1a can help treat patients with COVID-19, this study drug will be compared to dexamethasone.
Study subjects will be treated daily with IV IFN beta-1a 10 μg or IV dexamethasone for 6 consecutive days while hospitalized and will undergo daily assessments while in hospital for a maximum of 28 days. Study specific assessments will be collected at pre-dose Day 1 through Day 28 (PD and PIM assessments), in addition, clinical routine assessments will be utilized for safety and efficacy assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receiving active drug: will receive two separate bolus injections one containing IFN-beta -1a and another injection containing Saline.
Drug: IFN beta-1a
Patients receiving active comparator: will receive two separate bolus injections one containing saline and another injection containing Dexamethasone.
Drug: Dexamethasone
Treated daily with IFN beta-1a 10 μg as an IV bolus for 6 days while hospitalised
Treated daily with dexamethasone 6 mg as an IV bolus for 6 days while hospitalised
Clinical Status at Day 14 (First Day of Study Drug is Day 1) as Measured by WHO 9-point Ordinal Scale
WHO 9-point ordinal scale: 0 - No detectable infection 1. - Not hospitalized, no limitations on activities 2. - Not hospitalized, limitation on activities 3. - Hospitalized, not requiring supplemental oxygen 4. - Hospitalized, requiring supplemental oxygen 5. - Hospitalized, on non-invasive ventilation or high flow oxygen devices 6. - Hospitalized, on invasive mechanical ventilation 7. - Hospitalized, on mechanical ventilation plus additional organ support: renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO) 8. - Death
Time frame: Day 14
In-hospital Mortality at Day 28 and Day 90
Percentage of participants per study group that die when in still hospital at Day 28 or Day 90 of the trial
Time frame: Day 28 and Day 90
Overall (All-cause) Mortality at Day 28 and Day 90
Percentage of participants per study group that die within 28 days or 90 days from starting the study
Time frame: Day 28 and Day 90
| Milestone | IV IFN Beta-1a | IV Dexamethasone |
|---|---|---|
| Started | 3 | 4 |
| Completed | 2 | 3 |
| Not completed | 1 | 1 |
| Withdrew: Screen failure, patient was not dosed | 1 | 1 |
WHO 9-point ordinal scale: 0 - No detectable infection 1. - Not hospitalized, no limitations on activities 2. - Not hospitalized, limitation on activities 3. - Hospitalized, not requiring supplemental oxygen 4. - Hospitalized, requiring supplemental oxygen 5. - Hospitalized, on non-invasive ventilation or high flow oxygen devices 6. - Hospitalized, on invasive mechanical ventilation 7. - Hospitalized, on mechanical ventilation plus additional organ support: renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO) 8. - Death
| units on a scale | IV IFN Beta-1a | IV Dexamethasone |
|---|---|---|
| Clinical Status at Day 14 (First Day of Study Drug is Day 1) as Measured by WHO 9-point Ordinal Scale | 2 ± 0 | 2 ± 0 |
Percentage of participants per study group that die when in still hospital at Day 28 or Day 90 of the trial
| Participants | IV IFN Beta-1a | IV Dexamethasone |
|---|---|---|
| In-hospital Mortality at Day 28 and Day 90 | 0 | 0 |
Percentage of participants per study group that die within 28 days or 90 days from starting the study
| Participants | IV IFN Beta-1a | IV Dexamethasone |
|---|---|---|
| Overall (All-cause) Mortality at Day 28 and Day 90 | 0 | 0 |
Collected over Adverse events are collected from the signing of consent up to Day 28. AEs occurring after D28 were to be reported only if the Investigator considers there is a causal relationship with the study drug. All AEs up to D90, which lead to death, are reported as SAEs.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IV IFN Beta-1a | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| IV Dexamethasone | 0/3 (0%) | 2/3 (66.7%) | 2/3 (66.7%) |
| Event | IV IFN Beta-1a | IV Dexamethasone |
|---|---|---|
| dehydrationMetabolism and nutrition disorders | 0/2 | 1/3 |
| head injuryInjury, poisoning and procedural complications | 0/2 | 1/3 |
| Event | IV IFN Beta-1a | IV Dexamethasone |
|---|---|---|
| HyperglycemiaMetabolism and nutrition disorders | 1/2 | 0/3 |
| HypokalemiaMetabolism and nutrition disorders | 1/2 | 0/3 |
| HypnoatremiaMetabolism and nutrition disorders | 1/2 | 0/3 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/2 | 0/3 |
| Subdural hematomaInjury, poisoning and procedural complications | 0/2 | 1/3 |
| SeizureNervous system disorders | 0/2 | 1/3 |
| Age, Continuous(years) | IV IFN Beta-1a | IV Dexamethasone | Total |
|---|---|---|---|
| Mean | 60.0 ± 7.00 | 55.8 ± 15.69 | 57.6 ± 12.03 |
| Sex: Female, Male(Participants) | IV IFN Beta-1a | IV Dexamethasone | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 1 | 2 | 3 |
| Ethnicity (NIH/OMB)(Participants) | IV IFN Beta-1a | IV Dexamethasone | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 3 | 3 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | IV IFN Beta-1a | IV Dexamethasone | Total |
|---|---|---|---|
| Black or African American | 1 | 1 | 2 |
| White and Other (not specified) | 0 | 2 | 2 |
| White | 2 | 1 | 3 |
| Eastern Cooperative Oncology Group (ECOG) status(Participants) | IV IFN Beta-1a | IV Dexamethasone | Total |
|---|---|---|---|
| 0: Able to carry out all normal activity without restriction | 3 | 3 | 6 |
| 2: Ambulatory and capable of all self-care but unable to carry out any work activities | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2021 to primary completion in Apr 2022, 7 months.
Results were first posted in Oct 2022, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interferon beta-1a
Faron Pharmaceuticals Ltd